# Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

> **NCT06817525** · PHASE2 · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)
- **DRUG:** 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)

## Key facts

- **NCT ID:** NCT06817525
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06817525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06817525, "Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06817525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*